Do not inject where the sk in has p its , is t hic k ened, or has l um ps
Insert the needle of the syringe through the center of the Retatrutide vial's rubber stopper
FDA applies four factors to determine whether a compounded drug is essentially a copy of a commercially available product: Same active ingredient semaglutide or tirzepatide Same route of administration subcutaneous injection Same dosage form injectable solution Same strength matching FDA-approved doses (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, etc.) If your compounded product meets these four criteria, it is essentially a copy of Ozempic, Wegovy, Mounjaro, or Zepbound and it is illegal to compound, prescribe, or dispense
Multiple slices in both the short-axis and axial imaging planes were obtained covering the entire cardiac fossa